e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 15, 2005
Targeted Genetics Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Washington
|
|
0-23930
|
|
91-1549568 |
| |
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 1100 Olive Way, Suite 100, Seattle, Washington
|
|
98101 |
| |
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code (206) 623-7612
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| |
|
|
¨
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers.
On August 15, 2005, the Board of Directors appointed a new member, Roger Hawley as a Class II
director. Mr. Hawley has served as Vice President, Commercial and Technical Operations of
InterMune Pharmaceuticals since July 2003. From October 2002 to July 2003, Mr. Hawley served as
Chief Commercial Officer at Prometheus Laboratories, Inc., a specialty pharmaceutical company. From
2001 to 2002, Mr. Hawley served as Vice President/General Manager of Sales and Marketing at Elan
Pharmaceuticals, Inc., a biopharmaceutical company. From 1987 to 2001, Mr. Hawley held various
management positions in corporate finance, sales, and marketing at GlaxoSmithKline, Inc. Mr. Hawley
holds a B.S. in accounting from Eastern Illinois University.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
TARGETED GENETICS
CORPORATION
|
|
| |
By: |
/s/ TODD E. SIMPSON
|
|
| |
|
Todd E. Simpson |
|
| |
|
Vice President, Finance and Administration and Chief Financial Officer,
Secretary and Treasurer
(Principal Financial and Accounting Officer) |
|
| |
Dated: August 15, 2005
3